Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Unity Biotechnology ( (UBX) ).
On March 8, 2025, UNITY Biotechnology appointed Dr. Yehia Hashad to its Board of Directors and Science Committee. Dr. Hashad, an experienced ophthalmologist and executive at Bausch + Lomb, brings over 25 years of leadership in global research and development. His expertise is expected to aid UNITY in advancing its UBX1325 program for diabetic macular edema and other ophthalmologic treatments, potentially enhancing the company’s strategic positioning in the biotechnology sector.
More about Unity Biotechnology
UNITY Biotechnology, Inc. is a biotechnology company focused on developing therapeutics to slow, halt, or reverse diseases of aging. The company’s current focus is on creating medicines that selectively eliminate or modulate senescent cells to provide transformative benefits in age-related ophthalmologic and neurologic diseases.
YTD Price Performance: 47.37%
Average Trading Volume: 252,615
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $28.31M
For a thorough assessment of UBX stock, go to TipRanks’ Stock Analysis page.